Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox

Robert J. Kreitman, Constance M. Yuan, Hao-Wei Wang, Hong Zhou, Mark Raffeld, Liqiang Xi, Evgeny Arons, Julie Feurtado, Lacey James, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Ira Pastan

Blood (2024) 144 (Supplement 1): 6791.

https://doi.org/10.1182/blood-2024-199569

Published: 2024

Journal Articles

A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia

Robert J. Kreitman, Hao-Wei Wang, Dana I. Delgado Colon, Hong Zhou, Evgeny Arons, Mark Raffeld, Liqiang Xi, Julie Feurtado, Lacey James, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Constance M. Yuan

Blood (2024) 144 (Supplement 1): 863.

https://doi.org/10.1182/blood-2024-202793

Published: 2024

Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7059.

https://doi.org/10.1182/blood-2024-201563

Published: 2024

Journal Articles

Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy

Jeremy C. McMurray, Curtis S. Pacheco, Brandon J. Schornack, Xiaoping Sun, Janet A. Brunader, Alexis E. Scott, Juan S. Ariza, Chung-Ting J. Kou, Ryan C. Costantino, Luke M. Pittman, Karla E. Adams, Aubri M. Waters, Eric M. Pryor, Jonathan J. Lyons, Dean D. Metcalfe, Irina Maric, Nathan A. Boggs

Blood (2024) 144 (4): 408–419.

https://doi.org/10.1182/blood.2023023347

Published: 2024

Includes: Supplemental data

Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Blood (2023) 142 (Supplement 1): 337.

https://doi.org/10.1182/blood-2023-181811

Published: 2023

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

Bone Marrow, Laboratory, and Clinical Features in Pediatric Patients with RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM)

Seila De Leon, Michelly Sampaio De Melo, Nisha Patel, Alina Dulau Florea, Irina Maric, Raul C. Braylan, Weixin Wang, Matthew Merguerian, Elizabeth J. Andrews, Lea Cunningham, David J. Young, Shawn Chong, Natalie Deuitch, Joie Davis, Kathleen Craft, Theo Heller, Pamela Frischmeyer-Guerrerio, Paul Pu Liu, Katherine R. Calvo

Blood (2023) 142 (Supplement 1): 4109.

https://doi.org/10.1182/blood-2023-187600

Published: 2023

Journal Articles

A rare case of well-differentiated systemic mastocytosis

Nisha Patel, Irina Maric

Blood (2023) 141 (19): 2403.

https://doi.org/10.1182/blood.2022019281

Published: 2023

Journal Articles

Eosinophilia in Vexas Syndrome: Expanding Hematologic Phenotype

Ashvind Anand Prabahran, Fernanda Gutierrez-Rodrigues, Serene Ahmad, Edward W Cowen, Ivana Darden, Emma M. Groarke, Marcela Ferrada, Peter C. Grayson, Amy D Klion, Katherine R. Calvo, Irina Maric, Neal S. Young, Bhavisha A. Patel

Blood (2022) 140 (Supplement 1): 2607–2608.

https://doi.org/10.1182/blood-2022-160287

Published: 2022

Journal Articles

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Katherine Weissler, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Hao-Wei Wang, Constance M. Yuan, David F. Stroncek, Steven Highfill, Micaela Ganadan, Rashmika Patel, Steven A Rosenberg, James N. Kochenderfer

Blood (2022) 140 (Supplement 1): 7433–7434.

https://doi.org/10.1182/blood-2022-159156

Published: 2022

Journal Articles

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Maryalice Stetler-Stevenson, Hao-Wei Wang, Constance M. Yuan, Tyler Lowe, David F. Stroncek, Steven Highfill, Rashmika Patel, Micaela Ganadan, Steven A Rosenberg, James N. Kochenderfer

Blood (2021) 138 (Supplement 1): 3837.

https://doi.org/10.1182/blood-2021-152688

Published: 2021

Journal Articles

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-138839

Published: 2020

Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Blood (2020) 136 (Supplement 1): 43–45.

https://doi.org/10.1182/blood-2020-136148

Published: 2020

Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Blood (2020) 136 (1): 93–105.

https://doi.org/10.1182/blood.2019003715

Published: 2020

Includes: Supplemental data

Journal Articles

Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation

Jack Y. Ghannam, Xin Xu, Irina Maric, Laura Dillon, Yuesheng Li, Matthew M. Hsieh, Christopher S. Hourigan, Courtney D. Fitzhugh

Blood (2020) 135 (14): 1185–1188.

https://doi.org/10.1182/blood.2019004001

Published: 2020

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Lekha Mikkilineni, MD, Elisabet E. Manasanch, MD, Norris Lam, BS, Danielle Vanasse, BS, Jennifer N. Brudno, MD, Irina Maric, MD MSci, Jeremy J. Rose, MS, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, David F. Stroncek, MD, Jennifer Mann, CRNP, Micaela Ganadan, BSN, RN, Rashmika Patel, Nathan Trinklein, PhD, Ben Buelow, MD PhD, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2019) 134 (Supplement_1): 3230.

https://doi.org/10.1182/blood-2019-129088

Published: 2019

Journal Articles

Immunophenotypic Patterns of Bone Marrow Eosinopoiesis in Patients with Hypereosinophillic Syndrome and Systemic Mastocytosis

Christopher Trindade, MD, Xiaoping Sun, PhD, Dragan Maric, PhD, Chunjie Jiang, Christopher S. Hourigan, DPhil FACP FRCP, Dean D. Metcalfe, MD, Amy Klion, MD, Irina Maric, MD MSci

Blood (2018) 132 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2018-99-118797

Published: 2018

Journal Articles

The Role of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow: A Study of 148 Cases

Gaurav K. Gupta, MD, Xiaoping Sun, PhD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Robert J. Kreitman, MD, Irina Maric, MD MSci

Blood (2018) 132 (Supplement 1): 4859.

https://doi.org/10.1182/blood-2018-99-116258

Published: 2018

NARROW

Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox

A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Bone Marrow, Laboratory, and Clinical Features in Pediatric Patients with RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM)

A rare case of well-differentiated systemic mastocytosis

Eosinophilia in Vexas Syndrome: Expanding Hematologic Phenotype

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Immunophenotypic Patterns of Bone Marrow Eosinopoiesis in Patients with Hypereosinophillic Syndrome and Systemic Mastocytosis

The Role of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow: A Study of 148 Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only